Clinical Trial Update: FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating second-line FOLFIRI with Bevacizumab, with or without Pelareorep, for Ras-mutated, microsatellite-stable metastatic col…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI regimen (irinotecan + leucovorin + 5-fluorouracil)
• Pelareorep (pelareorep)

Snippet

Sponsor: Oncolytics Biotech | Conditions: Ras-mutated Metastatic Colorectal Cancer, mCRC | Phase 2 | Status: RECRUITING